Use of aliginate oligomers and CFTR modulators in treatment of conditions associated with CFTR dysfunction

US10751363B2 · kind B2 · utility

Assignee

• AlgiPharma AS · NO

Inventors

• Arne Dessen · Røyken, NO
• Astrid Hilde Myrset · Oslo, NO
• Philip Rye · Oslo, NO

Key dates

• Filing date: Mar 23, 2016
• Grant date: Aug 25, 2020
• Expiry date: Mar 23, 2036

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61P11/00
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

A method is for the treatment of a condition in a subject, which arises from or is associated with CFTR dysfunction. The method includes administering to the subject an effective amount of a CFTR modulator together with an effective amount of an alginate oligomer. The condition can be cystic fibrosis (CF), non-compound CFTR gene mutation heterozygosity, abnormal mucus clearance in the respiratory tract and/or breathing difficulties resulting from chronic particulate inhalation, COPD, chronic bronchitis, emphysema, bronchiectasis, asthma or chronic sinusitis, or a complication of any of these.